drugset
drugset / Trial / NCT02303769

Study to Investigate the Efficacy and Safety of GL2702 GLARS-NF1tablet and Harnal-D - Tablet in BPH Patients With LUTS

NCT02303769 ↗

Phase 3 Completed 309 enrolled GL Pharm Tech Corporation
RandomizedParallel-groupTriple-blindTreatment

Summary

Study to investigate the efficacy and safety of GL2702 GLARS-NF1tablet and Harnal-D - tablet in benign prostatic hyperplasia patients with lower urinary tract symptomatic

Timeline

Start
2014-03
Primary completion
2015-05
Completion
2015-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Tamsulosin Other / unclassified 0.2 mg —
Subject Tamsulosin Other / unclassified 0.4 mg —

Indications

benign prostatic hyperplasia